)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Sana Biotechnology (SANA) investor relations material
Sana Biotechnology Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Prioritized SC451 (type 1 diabetes) and SG293 (in vivo CAR T) programs, suspending allogeneic CAR T programs SC291 and SC262 to focus resources on most promising assets.
Announced positive 12-week and six-month results from the UP421 trial, showing survival, function, and immune evasion of transplanted beta cells without immunosuppression in type 1 diabetes patients.
Completed public offerings and ATM equity sales in 2025, raising $133.2 million in gross proceeds and $109.2 million in net proceeds.
Financial highlights
Net loss for Q3 2025 was $42.2 million ($0.16/share), and $185.3 million ($0.75/share) for the nine months ended September 30, 2025, both improved from 2024.
Research and development expenses for Q3 2025 were $30.1 million, down from $53.2 million in Q3 2024; for the nine months ended September 30, 2025, R&D expenses were $97.1 million, down from $170.5 million in 2024.
General and administrative expenses for Q3 2025 were $10.3 million, down from $14.1 million in Q3 2024; for the nine months ended September 30, 2025, G&A expenses were $32.1 million, down from $46.8 million in 2024.
Cash, cash equivalents, and marketable securities totaled $153.1 million as of September 30, 2025.
Non-GAAP net loss for Q3 2025 was $39.0 million ($0.15/share), and $125.4 million ($0.51/share) for the nine months, both improved year-over-year.
Outlook and guidance
Cash and recent equity proceeds expected to fund operations for at least one year from the filing date, with runway projected into late 2026.
Anticipates need for additional financing in the future to support ongoing operations and clinical development.
Plans to file IND for SC451 as early as 2026 and for SG293 as early as 2027.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sana Biotechnology earnings date
TD Cowen Immunology and Inflammation Summit12 Nov, 2025
Next Sana Biotechnology earnings date
TD Cowen Immunology and Inflammation Summit12 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Sana Biotechnology Inc. is a biotechnology company focusing on the development of engineered cells as medicines. The company focuses on both ex vivo and in vivo cell engineering platforms to address a variety of therapeutic areas with significant unmet needs, including oncology, diabetes, central nervous system disorders, and autoimmune diseases among others. Sana Biotechnology's approach involves the use of cutting-edge technologies such as CRISPR for gene editing and their proprietary platforms, Fusogen for in vivo cell engineering, and a hyperimmune platform for ex vivo cell engineering. They are actively investigating potential treatments for conditions such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, and diabetes, to name a few. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage